{"analyses":[{"ciLowerLimit":"7.336","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"31.623","groupDescription":"Odds ratio: CZP/Placebo and p-value were calculated using logistic regression with factors for treatment, region and Magnetic Resonance Imaging/C- Reactive Protein (MRI/CRP) classification.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"15.231","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0"},{"groupId":"OG001","value":"47.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"159"}],"units":"Participants"}],"description":"This variable was considered as primary in all countries except for Canada (and any other country where applicable or where requested by Regulatory Authorities) where it was considered as secondary variable.\n\nASDAS-MI was achieved when there was a reduction (improvement) \\>= 2.0 in the ASDAS relative to Baseline, or when the lowest possible ASDAS score (0.6) was reached.\n\nThe ASDAS was calculated as the sum of the following components:\n\n0.121 × Back pain (BASDAI Q2 result) 0.058 × Duration of morning stiffness (BASDAI Q6 result) 0.110 × Patient's Global Assessment of Disease Activity (PGADA) 0.073 × Peripheral pain/swelling (BASDAI Q3 result) 0.579 × (natural logarithm \\[ln\\] of the (CRP \\[mg/L\\] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue were all assessed on a numerical scale (0 to 10 units, where 0 is \"not active\" and 10 is \"very active\").","groups":[{"description":"Matching placebo to certolizumab pegol (CZP) injections were administered every 2 weeks from Week 0 onwards. Subjects formed the Full Analysis Set (FAS).","id":"OG000","title":"Placebo (FAS)"},{"description":"Certolizumab pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards. Subjects formed the FAS.","id":"OG001","title":"CZP 200 mg Q2W (FAS)"}],"paramType":"NUMBER","populationDescription":"The FAS consisted of all subjects in the RS who have received at least 1 dose of study medication.","reportingStatus":"POSTED","timeFrame":"Week 52","title":"Percentage of Subjects With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) Response Criteria Response at Week 52","type":"PRIMARY","unitOfMeasure":"percentage of subjects"}